Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK501635PMID: 30000696
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 163222-33-1
Drug Levels and Effects
Summary of Use during Lactation
No relevant published information exists on the use of ezetimibe during breastfeeding. Because of a concern with disruption of infant lipid metabolism, ezetimibe is best avoided during breastfeeding. An alternate drug is preferred, especially while nursing a newborn or preterm infant. Ezetimibe treatment in combination with a statin (e.g., atorvastatin, simvastatin) should be avoided in nursing mothers.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Substance Identification
Substance Name
Ezetimibe
CAS Registry Number
163222-33-1
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- LactMed App
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia).[Drug Metab Dispos. 2004]Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia).Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, Alton K, Patrick JE, Zbaida S. Drug Metab Dispos. 2004 Mar; 32(3):314-20.
- Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.[J Med Chem. 1998]Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.Rosenblum SB, Huynh T, Afonso A, Davis HR Jr, Yumibe N, Clader JW, Burnett DA. J Med Chem. 1998 Mar 12; 41(6):973-80.
- Review Fluvastatin.[Drugs and Lactation Database (...]Review Fluvastatin.. Drugs and Lactation Database (LactMed®). 2006
- Review Simvastatin.[Drugs and Lactation Database (...]Review Simvastatin.. Drugs and Lactation Database (LactMed®). 2006
- Review Pitavastatin.[Drugs and Lactation Database (...]Review Pitavastatin.. Drugs and Lactation Database (LactMed®). 2006
- Ezetimibe - Drugs and Lactation Database (LactMed®)Ezetimibe - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...